We recently reported a high ORR of 50% with durable responses in a multicenter analysis of 14 metastatic MCC patients with primary resistance to the PD-L1 inhibitor avelumab who were subsequently treated with combined ICI with IPI/NIVO. Here, CD274 is linked to Merkel cell skin cancer.